KCT0000568终止未知
Morning to evening ratio in total dose of twice-daily biphasic insulin analog in achieving glucose control in patients with poorly controlled type 2 diabetes
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 20(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1) Subjects aged more than 20 years old
- •2) Subjects with type 2 diabetes who were on sulphonylurea for glucose control
- •i) more than 7.5% A1c level at the time of enrollment
- •3) Subjects who have willingness to keep the protocl
- •4) Subjects who consent in written form
排除标准
- •1) Cancer patients who currently on or will be scheduled for chemotherapy or radition therapy within 6 months.
- •2) Subjects with renal failure who currently on or will be scheduled for hemodialyisis therapy within 6 months
- •3) Subjects with heart failure (more than NYHA stage 3)
- •Subjects with liver failure (more than Child-Pugh class B)
- •4) Gestational diabetes, type 1 diabetes and secondary yperglycemia, such as iatrogenic,inflammatory, or endocrine disorders, and liver cirrhosis.
- •5) Subjects who do not consent the study
研究者
相似试验
进行中（未招募）
1 期
Alternative iron replacement therapy in patients with iron deficiency after weight loss surgery.EUCTR2021-001953-30-ATVerein zur Förderung der Wissenschaft und Forschung an der 1. Med. Abteilung der Klinik Landstraße60
已完成
不适用
Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomised controlled studyAllergic rhinitisSeasonal allergic rhinitisRespiratoryISRCTN23032971Schering-Plough AS (Norway)663
尚未招募
不适用
A Comparative study of different dosing regimens in children with irondeficiency anemiaCTRI/2023/01/048846Amith k
已完成
不适用
Comparison of morning vs evening dosing of the latanoprost/timolol maleate fixed combination (Xalacom) on intraocular pressure control in primary open angle glaucoma. -Pilot Studyprimary open angle glaucomaJPRN-UMIN000011275Department of Ophthalmology, Kanazawa University40
进行中（未招募）
不适用
Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.Renal Cell Cancer, GIST, pancreatic neuroendocrine tumorMedDRA version: 14.1Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10055008Term: Gastric sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000425-45-NL18